RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Tarsus Pharmaceuticals Stock

Tarsus Pharmaceuticals ROE 2024

Tarsus Pharmaceuticals ROE

-0.69

Ticker

TARS

ISIN

US87650L1035

In 2024, Tarsus Pharmaceuticals's return on equity (ROE) was -0.69, a 114.32% increase from the -0.32 ROE in the previous year.

Tarsus Pharmaceuticals Aktienanalyse

What does Tarsus Pharmaceuticals do?

Tarsus Pharmaceuticals Inc is an emerging pharmaceutical company specializing in the development of novel therapies for eye diseases. The company was founded in 2016 and is headquartered in Irvine, California. Tarsus focuses on identifying groundbreaking innovative technologies and drugs for the treatment of eye diseases. Tarsus's business model is based on the idea that there are still no effective treatment methods for many eye diseases. For this reason, the company invests in research and development to close this gap and give affected patients new hope. Tarsus's goal is to improve eye health through the development of drugs and therapies. Tarsus is divided into several divisions that focus on different areas of ophthalmology. These include the development of drugs for the treatment of dry eyes, eyelid twitching, age-related macular degeneration, and other eye diseases. Tarsus's first product, TP-03, is a medication for the treatment of conjunctivitis caused by the bacterium Demodex. This condition affects millions of people worldwide and is often difficult to treat. TP-03 is a novel medication specifically targeting Demodex, thus providing an effective treatment option. Another product from Tarsus is TP-04, a medication for the treatment of dry eyes. This condition is one of the most common eye diseases worldwide, affecting millions of people. TP-04 aims to combat the causes of dry eyes and alleviate the symptoms. Tarsus also has a promising pipeline of products in various stages of development. These include medications for age-related macular degeneration, eyelid twitching, and other eye diseases. Tarsus has entered into partnerships with major pharmaceutical companies and research institutions. These partnerships allow the company to bring its products to market faster and reach a larger audience. Overall, Tarsus has the potential to revolutionize ophthalmology and improve the treatment of many eye diseases. The company has a dedicated team of researchers and scientists who are committed to advancing the development of new therapies and medications. Tarsus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Tarsus Pharmaceuticals's Return on Equity (ROE)

Tarsus Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Tarsus Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Tarsus Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Tarsus Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Tarsus Pharmaceuticals stock

What is the ROE (Return on Equity) of Tarsus Pharmaceuticals this year?

The ROE of Tarsus Pharmaceuticals this year is -0.69 undefined.

How has the Return on Equity (ROE) of Tarsus Pharmaceuticals developed compared to the previous year?

The ROE of Tarsus Pharmaceuticals has increased by 114.32% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Tarsus Pharmaceuticals?

A high ROE indicates that Tarsus Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Tarsus Pharmaceuticals?

A low ROE can indicate that Tarsus Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Tarsus Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Tarsus Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Tarsus Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Tarsus Pharmaceuticals?

Some factors that can influence Tarsus Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Tarsus Pharmaceuticals pay?

Over the past 12 months, Tarsus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Tarsus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Tarsus Pharmaceuticals?

The current dividend yield of Tarsus Pharmaceuticals is .

When does Tarsus Pharmaceuticals pay dividends?

Tarsus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Tarsus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Tarsus Pharmaceuticals located?

Tarsus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Tarsus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Tarsus Pharmaceuticals from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did Tarsus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of Tarsus Pharmaceuticals in the year 2023?

In the year 2023, Tarsus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Tarsus Pharmaceuticals pay out the dividend?

The dividends of Tarsus Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Tarsus Pharmaceuticals

Our stock analysis for Tarsus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Tarsus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.